Age-related macular degeneration patients who received injections of retinal cells derived from donors’ induced pluripotent stem cells have maintained their level of eyesight for a year.

Although the oral treatment seems to work, an analysis of the results from 12 clinical trials finds kids who got an immunotherapy have a greater rate of serious reactions.

Take a break from the bench to puzzle and peruse.

The publication of the SCIPIO trial is among many by Piero Anversa’s lab that Harvard Medical School flagged for fraudulent data.

The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.

The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.

Two studies show signs that the introduced DNA is functioning, but it’s too early to know if patients actually benefit.

YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.